Clinical and economic review report : Celltrion Healthcare Co., Ltd. : indication : rheumatoid arthritisInfliximab SC (Remsima)
This tailored review assesses the efficacy, safety, and cost associated with the SC form of biosimilar infliximab (Remsima SC, with a NOC status of completed on January 28, 2021) for the treatment of patients with RA. The new formulation consists of a solution for SC administration (120 mg/mL) in a 1 mL pre-filled syringe. Remsima SC is expected to be the first SC formulation of infliximab, aimed at patients who are initiating infliximab therapy (maintenance after 2 IV doses) or who are currently receiving infliximab IV maintenance therapy and are suitable to be switched to the SC formulation. The potential advantage for patients is a formulation that can be easily self-administered at home -- of particular interest in the current COVID-19 pandemic -- with better preparation time, patient convenience, and adherence, resulting in optimization of medical resources..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
August 2021 |
|---|---|
| Erschienen: |
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; August 2021 |
| Ausgabe: |
Version: Final (with redactions). |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed November 3, 2022) |
|---|
| Umfang: |
1 online resource (1 PDF file (70 pages)) ; illustrations |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1826460195 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1826460195 | ||
| 003 | DE-627 | ||
| 005 | 20230426074521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221207s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1826460195 | ||
| 035 | |a (DE-599)KEP083115315 | ||
| 035 | |a (OCoLC)1353598099 | ||
| 035 | |a (NCBI)9918486467706676 | ||
| 035 | |a (EBP)083115315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Clinical and economic review report |b Celltrion Healthcare Co., Ltd. : indication : rheumatoid arthritisInfliximab SC (Remsima) |
| 250 | |a Version: Final (with redactions). | ||
| 264 | 1 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c August 2021 | |
| 300 | |a 1 online resource (1 PDF file (70 pages)) |b illustrations | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed November 3, 2022) | ||
| 520 | |a This tailored review assesses the efficacy, safety, and cost associated with the SC form of biosimilar infliximab (Remsima SC, with a NOC status of completed on January 28, 2021) for the treatment of patients with RA. The new formulation consists of a solution for SC administration (120 mg/mL) in a 1 mL pre-filled syringe. Remsima SC is expected to be the first SC formulation of infliximab, aimed at patients who are initiating infliximab therapy (maintenance after 2 IV doses) or who are currently receiving infliximab IV maintenance therapy and are suitable to be switched to the SC formulation. The potential advantage for patients is a formulation that can be easily self-administered at home -- of particular interest in the current COVID-19 pandemic -- with better preparation time, patient convenience, and adherence, resulting in optimization of medical resources. | ||
| 650 | 2 | |a Arthritis, Rheumatoid |x drug therapy | |
| 650 | 2 | |a Antirheumatic Agents | |
| 650 | 2 | |a Treatment Outcome | |
| 650 | 2 | |a Cost-Benefit Analysis | |
| 651 | 2 | |a Canada | |
| 655 | 2 | |a Tables | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK584318/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 4228599338 |h h64 NCBI |y zi06404 |z 08-12-22 | ||
| 980 | |2 40 |1 01 |x 0007 |b 4228598145 |h OLR-NCB-BOOKSHELF |y xsn |z 08-12-22 | ||
| 980 | |2 74 |1 01 |x 0354 |b 422859722X |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-12-22 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 4228093892 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 07-12-22 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 4228094538 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 07-12-22 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 4228094546 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 07-12-22 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK584318/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK584318/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK584318/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK584318/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK584318/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||